The goal of the study was to evaluate the therapeutic efficacy of the Monoclonal anti-CD20 Antibody Rituximab and the increase of chemotherapy cycles from 6 to 8.


RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.

help Contributor and Creators

Views: 35

Created: 16th May 2019 at 14:02

Last updated: 20th May 2019 at 11:49

Related items

Powered by
Seek new full
Copyright © 2008 - 2019 The University of Manchester and HITS gGmbH
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig